United States - English - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - leflunomide (unii: g162gk9u4w) (leflunomide - unii:g162gk9u4w) - leflunomide 10 mg - arava is indicated for the treatment of adults with active rheumatoid arthritis (ra). arava is contraindicated in: - pregnant women. arava may cause fetal harm. if a woman becomes pregnant while taking this drug, stop arava, apprise the patient of the potential hazard to the fetus, and begin a drug elimination procedure [see warnings and precautions (5.1, 5.3) and use in specific populations (8.1)] . - patients with severe hepatic impairment [see warnings and precautions (5.2)] . - patients with known hypersensitivity to leflunomide or any of the other components of arava. known reactions include anaphylaxis [see adverse reactions (6.1)] . - patients being treated with teriflunomide [see drug interactions (7)] . pregnancy exposure registry there is a pregnancy exposure

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - leflunomide (unii: g162gk9u4w) (leflunomide - unii:g162gk9u4w) - leflunomide 495 g in 500 g

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - leflunomide (unii: g162gk9u4w) (leflunomide - unii:g162gk9u4w) - leflunomide 99 g in 100 g

Canada - English - Health Canada

sanis health inc - leflunomide - tablet - 10mg - leflunomide 10mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

sanis health inc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - leflunomide, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; maize starch; magnesium stearate; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions). lunava is not indicated for the treatment of psoriatic arthritis or psoriasis (whether or not associated with manifestations of psoriatic arthritis).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - leflunomide, quantity: 20 mg - tablet, film coated - excipient ingredients: povidone; colloidal anhydrous silica; maize starch; microcrystalline cellulose; magnesium stearate; crospovidone; lactose monohydrate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - treatment of active rheumatoid arthritis. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions). lunava is not indicated for the treatment of psoriatic arthritis or psoriasis (whether or not associated with manifestations of psoriatic arthritis).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - leflunomide, quantity: 10 mg - tablet, film coated - excipient ingredients: maize starch; microcrystalline cellulose; povidone; magnesium stearate; crospovidone; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions). lunava is not indicated for the treatment of psoriatic arthritis or psoriasis (whether or not associated with manifestations of psoriatic arthritis).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; maize starch; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; maize starch; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - treatment of active rheumatoid arthritis.,treatment of active psoriatic arthritis. leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).